Differentiating benign notochordal cell tumors from chordomas: radiographic features on MRI, CT, and tomography

…, M Ohsawa, T Inoue, K Kageyama… - American Journal of …, 2011 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this study was to characterize the imaging spectrum of benign
notochordal cell tumors (BNCTs) and chondromas and to determine if this helped in …

Co-targeting HGF/cMET signaling with MEK inhibitors in metastatic uveal melanoma

…, C Liao, TJ Purwin, M Terai, K Kageyama… - Molecular cancer …, 2017 - AACR
Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing
an urgent need to develop new treatment strategies. The liver is the most common site of …

Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma

H Cheng, M Terai, K Kageyama, S Ozaki, PA McCue… - Cancer research, 2015 - AACR
Uveal melanoma patients with metastatic disease usually die within one year, emphasizing
an urgent need to develop new treatment strategies for this cancer. MEK inhibitors improve …

[HTML][HTML] Development and validation of a deep learning model for detection of breast cancers in mammography from multi-institutional datasets

…, M Shiba, M Morimura, T Shimono, K Kageyama… - Plos one, 2022 - journals.plos.org
Objectives The objective of this study was to develop and validate a state-of-the-art, deep
learning (DL)-based model for detecting breast cancers on mammography. Methods …

[HTML][HTML] Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis

K Kageyama, M Ohara, K Saito, S Ozaki… - Journal of translational …, 2017 - Springer
Background Metastatic uveal melanoma is a highly fatal disease; most patients die from their
hepatic metastasis within 1 year. A major drawback in the development of new treatments …

Radiofrequency ablation and immunostimulant OK-432: combination therapy enhances systemic antitumor immunity for treatment of VX2 lung tumors in rabbits

S Hamamoto, T Okuma, A Yamamoto, K Kageyama… - Radiology, 2013 - pubs.rsna.org
Purpose To evaluate whether antitumor immunity is enhanced systemically by combining
radiofrequency ablation (RFA) and local injection of an immunostimulant, OK-432. Materials …

[HTML][HTML] Arterial blood, rather than venous blood, is a better source for circulating melanoma cells

…, Z Mu, DJ Eschelman, CF Gonsalves, K Kageyama… - …, 2015 - thelancet.com
Background CTCs provide prognostic information and their application is under investigation
in multiple tumor types. Of the multiple variables inherent in any such process, none is …

[HTML][HTML] Splenic vein diameter is a risk factor for the portal venous system thrombosis after partial splenic artery embolization

…, A Jogo, MM Nakano, K Kageyama… - Cardiovascular and …, 2021 - Springer
Purpose Portal venous system thrombosis is a complication of partial splenic artery embolization,
and pre-treatment risk assessment is thus important. The purpose of this study was to …

[HTML][HTML] Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis

…, E Kawamura, A Hagihara, H Fujii, K Kageyama… - Journal of …, 2023 - Springer
Background It is unclear whether hepatocyte function and/or portal hypertension improves if
a sustained virologic response (SVR) is achieved with direct-acting antivirals in patients with …

Lenvatinib-induced tumor-related hemorrhages in patients with large hepatocellular carcinomas

S Uchida-Kobayashi, K Kageyama, A Yamamoto… - Oncology, 2021 - karger.com
Introduction: Lenvatinib has been approved as a systemic therapy for patients with unresectable
hepatocellular carcinoma (HCC). We recently experienced lenvatinib-induced tumor-…